持续糖尿病性黄斑水肿患者继续雷珠单抗治疗时加用地塞米松的效果:DRCR网络2期随机临床试验
这项2期多中心随机临床试验在美国40个中心纳入116名成人糖尿病患者的129只眼,比较持续玻璃体内注射雷珠单抗单药与联合玻璃体内地塞米松植入物治疗持续性糖尿病性黄斑水肿。第24周时,联合组与雷珠单抗组视力字母评分改善无显著差异,联合组黄斑中心亚区厚度下降更多,但眼压升高或启用降压滴眼液的比例更高。
要点
- 第24周视力字母评分变化联合组2.7 vs 雷珠单抗组3.0,校正组间差异-0.5字母(95%CI -3.6至2.5;P=.73)。
- 黄斑中心亚区厚度变化联合组-110 μm vs 雷珠单抗组-62 μm,校正差异-52(95%CI -82至-22;P<.001)。
- 联合组19只眼(29%)出现眼压升高或启用降压滴眼液,雷珠单抗组为0(P<.001)。
核心结论
- 在抗VEGF治疗后持续性糖尿病性黄斑水肿眼中,继续雷珠单抗治疗时加用玻璃体内地塞米松虽更可能降低视网膜厚度并升高眼压,但第24周视力改善并不优于继续雷珠单抗单药治疗。
研究设计与样本
- 2期多中心随机临床试验,2014年2月至2016年12月在美国40个中心开展,纳入116名成人糖尿病患者的129只眼,按意向治疗分析。
- 入组眼为持续性糖尿病性黄斑水肿,导入期前至少接受3次抗VEGF注射,视力20/32至20/320;导入期包括额外3次每月0.3 mg雷珠单抗注射。
- 导入期后持续存在糖尿病性黄斑水肿且符合条件的研究眼随机接受700 μg地塞米松(联合组65只眼)或假治疗(雷珠单抗组64只眼),两组均继续0.3 mg雷珠单抗,依据结构化再治疗方案的频率最多每4周一次。
主要发现
- 随机化时中位年龄65岁(四分位距58-71岁),女性占50.9%,白人占60.3%。
- 从随机化起视力平均(SD)改善联合组2.7(9.8)字母 vs 雷珠单抗组3.0(7.1)字母,校正组间差异(联合减雷珠单抗)-0.5字母(95%CI -3.6至2.5;双侧P=.73)。
- 黄斑中心亚区厚度平均(SD)变化联合组-110(86)μm vs 雷珠单抗组-62(97)μm,校正差异-52(95%CI -82至-22;双侧P<.001)。
- 联合组19只眼(29%)出现眼压升高或开始使用降压滴眼液,雷珠单抗组0只眼(双侧P<.001)。
关键数值与推荐
- 主要结局为第24周电子早期治疗糖尿病视网膜病变研究(E-ETDRS)视力字母评分平均变化。
- 主要次要结局为光学相干断层扫描测量的黄斑中心亚区厚度平均变化。
- 联合组地塞米松剂量700 μg,两组雷珠单抗剂量均为0.3 mg,依据结构化再治疗方案的频率最多每4周一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone. OBJECTIVE: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 multicenter randomized clinical trial conducted at 40 US sites in 129 eyes from 116 adults with diabetes between February 2014 and December 2016. Eyes had persistent DME, with visual acuity of 20/32 to 20/320 after at least 3 anti-VEGF injections before a run-in phase, which included an additional 3 monthly 0.3-mg ranibizumab injections. Data analysis was according to intent to treat. INTERVENTIONS: Following the run-in phase, study eyes that had persistent DME and were otherwise eligible were randomly assigned to receive 700 μg of dexamethasone (combination group, 65 eyes) or sham treatment (ranibizumab group, 64 eyes) in addition to continued 0.3-mg ranibizumab in both treatment arms as often as every 4 weeks based on a structured re-treatment protocol. MAIN OUTCOMES AND MEASURES: The primary outcome was change in mean visual acuity letter score at 24 weeks as measured by the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS). The principal secondary outcome was change in mean central subfield thickness as measured with the use of optical coherence tomography. RESULTS: Of the 116 randomized patients, median age was 65 years (interquartile range [IQR], 58-71 years); 50.9% were female and 60.3% were white. Mean (SD) improvement in visual acuity from randomization was 2.7 (9.8) letters in the combination group and 3.0 (7.1) letters in the ranibizumab group, with the adjusted treatment group difference (combination minus ranibizumab) of -0.5 letters (95% CI, -3.6 to 2.5; 2-sided P = .73). Mean (SD) change in central subfield thickness in the combination group was -110 (86) μm compared with -62 (97) μm for the ranibizumab group (adjusted difference, -52; 95% CI, -82 to -22; 2-sided P < .001). Nineteen eyes (29%) in the combination group experienced increased intraocular pressure or initiated treatment with antihypertensive eyedrops compared with 0 in the ranibizumab group (2-sided P < .001). CONCLUSIONS AND RELEVANCE: Although its use is more likely to reduce retinal thickness and increase intraocular pressure, the addition of intravitreous dexamethasone to continued ranibizumab therapy does not improve visual acuity at 24 weeks more than continued ranibizumab therapy alone among eyes with persistent DME following anti-VEGF therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01945866.
引用
- Maturi RK, Glassman AR, Liu D, et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018. PMID: 29127949. doi:10.1001/jamaophthalmol.2017.4914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。